Andrew Slee

Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA.

Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA.

Vertical Ventures LLC provides investment and commercial real estate assets development services. The private company is based in New York, NY and has subsidiaries in the United States. The company was founded by Richard Kenneth Abbe.

Tekla Capital Management LLC is an independent, SEC-registered investment advisor headquartered in Boston, Massachusetts. Formerly known as Hambrecht & Quist Capital Management LLC, the firm serves as an investment adviser for four closed-end funds – Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund.

Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million.

Iroquois Capital LP engages in providing investment advice services. The company was founded by Joshua N. Silverman in 2002 and is headquartered in New York, NY.

Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz.

Iroquois Capital Management LLC (Iroquois Capital) is an independent hedge fund management firm headquartered in Scarsdale, New York. The firm was founded by Ricahrd Abbe, Joshua Silverman and Scot Cohen in 2003. Iroquois Capital provides discretionary advice to funds that are formed as pooled investment vehicles. Investors in the funds include high net-worth individuals, family offices, pension plans and other institutional investors.

Joele Frank, Wilkinson Brimmer Katcher provides public relations services. It offers corporate communication, investor relations, transaction communications, shareholder activism, crisis communication, and litigation support. The company was founded by Joele Frank in 2000 and is headquartered in New York, NY.

Decipher Biosciences, Inc. is a commercial-stage precision oncology company which engages in patient care improvement. The Company?s differentiated approach measures the biological activity of a patient?s entire tumor genome, known as whole transcriptome analysis, and applies proprietary machine learning algorithms to improve therapy selection and accelerate adoption of new therapies into the standard of care. Its novel prostate cancer genomic testing products examine the underlying biology of a patient?s tumor, enabling physicians to select an optimal therapy. The firm?s whole transcriptome analysis of clinical patient samples from its commercial channel and its participation in practice-changing clinical trials has allowed it to build and expand its Decipher GRID database GRID. The company was founded by Elai Davicioni, Timothy J. Triche, Bruce A. Schmidt, and Jonathan D. Buckley and is headquartered in San Diego, CA.

Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland.

Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France.

Parkfield Funding LLC provides capital management services. The private company is based in New York, NY. The company was founded by Joshua Nathaniel Silverman.

Crellin Capital LLC provides investment advisory and asset management services. The private company is based in Phoenix, AZ.

CuraSen Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapies to treat neurodegenerative diseases, including parkinson, alzheimer, and less common neurodegenerative disorders. The company was founded by Mehrdad Shamloo, Robert Booth, Anthony Ford, and Kathleen Sereda in 2018 and is headquartered in San Mateo, CA.

GenomeDx, Inc. operates as a genomic information company developing solutions for prostate cancer treatment and the management of other urologic cancers. It offers Decipher and Guidance test. The company is headquartered in San Diego, CA.

Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA.

Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen.

Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland.